Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Fig. 3

Survival analysis of postoperative breast cancer patients who received adjuvant CIK cell treatment (CIK treatment group, n = 150) compared to those who did not have CIK cell treatment (control group, n = 160). a Overall survival (OS) curves and (b) Recurrence-free survival (RFS) curves. Significantly improved prognosis was observed in the CIK treatment group compared to the control group. The Kaplan-Meier method was used to compare the survival rates, which were analyzed with the log-rank test

Back to article page